SCHEMBL960673

SCHEMBL960673

CN(C)C(=O)CCC(N)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
CHRNB2 P17787 1/20 0.41
CHRNB4 P30926 1/20 0.41
CHRNA4 P43681 1/20 0.41
PHF8 Q9UPP1 1/20 0.37
KDM2A Q9Y2K7 1/20 0.37
HSD17B10 Q99714 2/20 0.33
KMT2A Q03164 2/20 0.32
TP53 P04637 2/20 0.32
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2C19 P33261 2/20 0.32
MEN1 O00255 1/20 0.32
FAAH O00519 1/20 0.32
SOAT1 P35610 1/20 0.32
ALOX15 P16050 4/20 0.32
BLM P54132 3/20 0.32
PMP22 Q01453 3/20 0.32
LMNA P02545 2/20 0.32
TDP1 Q9NUW8 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3350624 0.97 ALDH1A1 (0.48) ALDH1A1CHRNB2CHRNB4CHRNA4PHF8
SCHEMBL7153729 0.86 ALDH1A1 (0.61) ALDH1A1CHRNB2CHRNB4CHRNA4PHF8
SCHEMBL1291925 0.86 ALDH1A1 (0.61) ALDH1A1CHRNB2CHRNB4CHRNA4PHF8
SCHEMBL1191256 0.85 ALDH1A1 (0.63) ALDH1A1CHRNB2CHRNB4CHRNA4PHF8
SCHEMBL28940937 0.84 ALDH1A1 (0.58) ALDH1A1CHRNB2CHRNB4CHRNA4PHF8
Hydrochloric Acid SCHEMBL19873292 0.84 ALDH1A1 (0.58) ALDH1A1CHRNB2CHRNB4CHRNA4KMT2A
SCHEMBL15254336 0.84 ALDH1A1 (0.58) ALDH1A1CHRNB2CHRNB4CHRNA4PHF8
Hydrochloric Acid SCHEMBL6214818 0.84 ALDH1A1 (0.58) ALDH1A1CHRNB2CHRNB4CHRNA4HSD17B10
SCHEMBL1160178 0.84 ALDH1A1 (0.58) ALDH1A1CHRNB2CHRNB4CHRNA4PHF8
SCHEMBL9853154 0.84 ALDH1A1 (0.58) ALDH1A1CHRNB2CHRNB4CHRNA4PHF8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108698992-B 2-cyanoisoindoline derivatives for the treatment of cancer 特殊治疗有限公司 2022-04-19 CN claimed
CN-109803948-B Warming sensation compound 高砂香料工业株式会社 2022-03-01 CN claimed
EP-3429994-B1 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER MISSION THERAPEUTICS LTD (GB) 2021-06-16 EP claimed
CN-108698992-A 2- cyano isoindoline derivatives for treating cancer 特殊治疗有限公司 2018-10-23 CN claimed
US-20170158684-A1 NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2017-06-08 US claimed
CN-106262580-A A kind of coolant agent N (4 methoxyphenyl) using method to menthyl 3 carboxylic acid amides 安徽丰乐香料有限责任公司 2017-01-04 CN claimed
US-20150336920-A1 NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2015-11-26 US claimed
CN-103501780-B Benzofuran-piperidine compounds HOFFMAN-LA ROCHE LTD. (CH) 2015-11-25 CN claimed
EP-2933254-A1 NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT Korea Research Institute of Chemical Technology (KR) 2015-10-21 EP claimed
CN-103787905-A Novel synthesis method for L-menthyl-N,N-dimethyl succinamide ANHUI FENGLE PERFUME CO LTD 2014-05-14 CN claimed
CN-103501780-A Novel benzofurane-piperidine compounds HOFFMANN LA ROCHE 2014-01-08 CN claimed
EP-2139894-A1 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS AstraZeneca AB (SE) 2010-01-06 EP claimed
WO-2008114006-A1 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS ASTRAZENECA AB (SE) 2008-09-25 WO claimed
CN-100347151-C Novel aminobenzophenones LEO PHARMA AS (DK) 2007-11-07 CN claimed
US-20050239832-A1 Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors ELAN PHARMACEUTICALS, INC. 2005-10-27 US claimed
CN-1561327-A Novel aminobenzophenones LEO PHARMA AS (DK) 2005-01-05 CN claimed
CN-1116192-A Composition and production method of special spraying fertilizer for crops SONG KAIQUAN (CN) 1996-02-07 CN claimed
US-20260034107-A1 SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS VTV THERAPEUTICS LLC (US) 2026-02-05 US disclosed
EP-0301932-A1 Insoluble polymer compound containing reactive condensed side chains, especially of the active anhydride group or ester type, process for the manufacture of this compound and use of this compound ACOME, SOCIETE COOPERATIVE DE TRAVAILLEURS (FR) 1989-02-01 EP disclosed
EP-0062161-B1 SYNTHESIS OF AMIDES USING CARBAMIC-ACID SALTS UNION CARBIDE CORPORATION (US) 1984-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034107-A1 SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS HBB, HBZ, HBG1 ALDH1A1 382/4885CHRNB2 1705/4885CHRNB4 2263/4885
US-20050239832-A1 Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors APP, DNPEP, BACE1 ALDH1A1 2677/4885CHRNB2 4009/4885CHRNB4 4309/4885
US-20170158684-A1 NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT RNASE1, HTRA1, IAPP ALDH1A1 2687/4885CHRNB2 2773/4885CHRNB4 2726/4885
US-20150336920-A1 NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT RNASE1, HTRA1, IAPP ALDH1A1 2687/4885CHRNB2 2773/4885CHRNB4 2726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.